HealthcareServices

Choroidal Neovascularization Market Expansion Outlook: $5.59 Billion by 2029 Forecast

November 27, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Choroidal Neovascularization Market By 2029?

The choroidal neovascularization market size has seen substantial growth over recent years. It is anticipated to expand from $3.88 billion in 2024 to $4.18 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.7%. This expansion in the past can be attributed to the increasing spread of sedentary lifestyle diseases, a growing prevalence of age-related macular degeneration, the rising occurrence of retinal illnesses, an expanding aged population, escalating eye care costs, and broader education and screening initiatives.

The choroidal neovascularization market is projected to experience substantial expansion in the coming years, set to reach $5.59 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.5%. Several factors will drive this growth during the forecast period, including heightened patient awareness, the increasing uptake of optical coherence tomography angiography, rising demand for minimally invasive treatments, supportive reimbursement frameworks, and an expanding elderly demographic. Key trends anticipated during this period encompass the introduction of intravitreal anti-vascular endothelial (VEGF) therapies, novel gene treatments, diverse gene therapy methodologies, the integration of telemedicine, the creation of combination therapies, and tailored treatment plans.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

Which Drivers Are Impacting The Choroidal Neovascularization Market?

The escalating occurrence of age-related macular degeneration (AMD) is anticipated to fuel the expansion of the choroidal neovascularization (CNV) market moving ahead. Age-related macular degeneration (AMD) is an ocular condition that progressively impairs the macula, resulting in the loss of central vision, predominantly among older individuals. The increasing incidence of age-related macular degeneration (AMD) stems from an aging demographic, extended lifespans, evolving lifestyle patterns, genetic predispositions, and heightened exposure to environmental hazards. Choroidal neovascularization (CNV) plays a role in assisting age-related macular degeneration (AMD) patients by facilitating the emergence of wet AMD, a condition where abnormal blood vessel proliferation under the retina leads to visual decline. This necessitates advanced interventions like anti-VEGF therapy to control choroidal neovascularization (CNV) and impede the advancement of age-related macular degeneration (AMD), thereby aiming to maintain central vision for those affected. As an illustration, in September 2022, data from the National Institutes of Health, a US-based government agency, indicated that by 2040, age-related macular degeneration (AMD) instances might reach 300 million, and by 2050, 5.4 million Americans could be affected. Consequently, the growing prevalence of age-related macular degeneration is propelling the development of the choroidal neovascularization market.

How Is The Choroidal Neovascularization Market Segmented?

The choroidal neovascularizationmarket covered in this report is segmented –

1) By Treatment Type: Anti-Angiogenic Therapy; Laser Photocoagulation; Photodynamic Therapy; Verteporfin Sodium; Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium

2) By Indication: Age-Related Macular Degeneration (AMD); Diabetic Macular Edema (DME); Central Serous Chorioretinopathy (CSC); Polypoidal Choroidal Vasculopathy (PCV); Myopic Macular Degeneration (MMD); Other Indications

3) By Route Of Administration: Intravitreal; Subconjunctival; Periocular; Oral

4) By End User: Hospitals; Ophthalmology Clinics; Ambulatory Surgical Centers; Research Centers

Subsegments:

1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium

2) By Laser Photocoagulation: Thermal Laser Photocoagulation; MicroPulse Laser Therapy

3) By Photodynamic Therapy (PDT): Standard PDT; Low-Fluence PDT; Half-Dose PDT

4) By Verteporfin Sodium: Intravenous Administration; Combination Therapy With Anti-VEGF

5) By Ranibizumab: Monthly Dosing; As-Needed Dosing; Treat-and-Extend Regimen

6) By Bevacizumab: Off-Label Use; Compounded Intravitreal Injections

7) By Aflibercept: Fixed-Dosing Regimen; Treat-and-Extend Regimen

8) By Pegaptanib Sodium: Monotherapy; Combination Therapy

What Trends Are Redefining The Choroidal Neovascularization Market Dynamics?

Major companies within the choroidal neovascularization market are concentrating on developing innovative treatments, including photodynamic therapy, to provide eye care professionals with precise, efficient options that enhance patient outcomes and improve treatment delivery. Photodynamic therapy (PDT) is a medical process that employs a photosensitizing agent activated by light to pinpoint and eliminate abnormal or cancerous cells. For instance, in February 2023, Bausch & Lomb, a Canada-based healthcare company, and Modulight, a Finland-based biomedical company, announced the ML6710i photodynamic laser had received approval from the Food and Drug Administration, a US-based federal agency. This therapy is sanctioned for use with Bausch + Lomb’s VISUDYNE therapy, which is specifically designed to treat choroidal neovascularization caused by age-related macular degeneration (AMD). This contemporary, mobile ophthalmic laser offers a targeted approach for addressing abnormal blood vessels in the eye, thereby contributing to preventing further disease progression and preserving vision.

Which Major Firms Are Strengthening Their Position In The Choroidal Neovascularization Industry?

Major companies operating in the choroidal neovascularization market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer Aktiengesellschaft, Novartis AG, Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Alcon Inc., Genentech Inc., Bausch + Lomb Incorporated, Samsung Bioepis Co. Ltd., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kodiak Sciences Inc., Xbrane Biopharma AB, Allergan Inc., Adverum Biotechnologies Inc., Clearside Biomedical Inc., Sylentis S.A.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

What Regional Growth Trends Are Shaping The Choroidal Neovascularization Market Outlook?

North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Choroidal Neovascularization Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21142&type=smp

Browse Through More Reports Similar to the Global Choroidal Neovascularization Market 2025, By The Business Research Company

Myopia And Presbyopia Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/myopia-and-presbyopia-treatment-global-market-report

Warship And Naval Vessels Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/warship-and-naval-vessels-global-market-report

Fiber Reinforced Plastic Vessels Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/fiber-reinforced-plastic-vessels-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795